Abstract 5495
Background
Digital biomarkers allow for continuous remote patient monitoring and will potentially change the way healthcare is provided and clinical trials are designed. We conducted a study to identify current preferences and interest in digital biomarkers in patients with advanced urological cancers.
Methods
We included 80 patients undergoing systemic therapy for advanced urologic malignancies at our institution. A questionnaire was developed to survey the current access to online information and digital technologies and to rate preferences on a scale from 1 (does not apply) to 5 (fully applies). Statistical analysis was performed by Chi-square test and unpaired t-test.
Results
26% of the cohort presented with prostate cancer (PC), 38% with urothelial cancer (UC) and 36% with renal cell carcinoma (RCC). 69% of patients researched medical information about their disease online, 85% of PC patients, 72% of RCC patients, and 53% of UC respectively. 63% of all patients use smartphones and 9% wearables. Smartphone usage is most common in RCC patients (76%) followed by PC (66%) and UC (46%) patients while wearables are used by 7% of RCC, 5% of PC, and 13% of UC patients, respectively. In our cohort RCC patients are younger (Mean 63.3 years) than PC patients (Mean 69.3 years) and UC patients (Mean 68.3 years). The percentage of patients seeking information online and using smartphones or wearables is significantly higher in patients under the age of 75 (p < 0.05). With respect to the information generated by wearables, patients’ interest in activity data is significantly higher (3.5/5) than interest in sleeping profiles (2.5/5; p < 0.01). Patients are more likely to use wearables in clinical trials when they have access to the generated activity data (2.8/5) than using them without gaining access to the information (2.1/5; p < 0.01). Interest in wearable data and willingness to wear them as part of clinical trials are significantly higher for male gender (p < 0.01), and is independent of age and distance between home and the clinical trial site.
Conclusions
Our study demonstrates a high engagement of patients in digital technologies. Even though there is a lower penetration rate for digital technologies in older people, interest in digital biomarker data is high in regardless of age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Severin Rodler.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract